<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461175</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2006_01</org_study_id>
    <nct_id>NCT00461175</nct_id>
  </id_info>
  <brief_title>European Active Surveillance Study for Intrauterine Devices</brief_title>
  <acronym>EURAS-IUD</acronym>
  <official_title>European Active Surveillance Study for Intrauterine Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the risks of intrauterine device (IUD) use in
      a study population that is representative for the actual users of the individual IUDs. The
      primary clinical outcome of interest is the uterine perforation rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a large, multinational, prospective, controlled, long-term cohort study that follows
      a series of cohorts. The cohorts consist of new users of different groups of intrauterine
      devices (IUDs). Primarily, a non-interference approach - with exception of the standardized
      diagnostic workup to identify uterine perforations - will be used to provide standardized,
      comprehensive and reliable information on these IUDs under routine medical conditions.

      The primary objective of the study is to assess the risks of intrauterine device (IUD) use in
      a study population that is representative for the actual users of the individual IUDs. The
      primary clinical outcome of interest is the uterine perforation rate. Secondary objectives
      are among others:

        -  the time intervals between IUD insertion and uterine perforation

        -  impact of post-partal IUD insertion on the uterine perforation rate

        -  proportion of uterine perforations associated with IUD insertion with serious clinical
           complications

        -  the incidences of medically relevant adverse events associated with IUP use

      The combined cohort will include 60000 women recruited in six European countries. Enrollment
      should begin in November 2006 and end in 2012. Patients should undergo follow-up for at least
      1 year.

      Recruitment of the cohort members will be conducted via a network of approximately 2000
      gynecologists.

      Enrollment procedures should not interfere with the prescribing behavior of physicians or
      with the individual needs of the participating women. Influence on the preference for
      specific oral contraceptives is to be avoided but significant efforts are to be undertaken to
      ensure standardized, comprehensive and reliable documentation of all baseline characteristics
      and adverse events during the follow-up period.

      The study participants are women aged 18 or older who have a new insertion of an IUD and who
      are willing to participate in this cohort study. There are no specific medical inclusion or
      exclusion criteria. However, women who are not cooperative may be excluded from study
      participation. Also women with a language barrier will not be eligible for study inclusion.

      This study will maintain scientific independence and will be governed by an independent
      Advisory Council. The Center for Epidemiology and Health Research in Berlin, Germany and its
      research team will be accountable for the Advisory Council (AC) in all scientific matters.
      The members of the AC wil be international experts in relevant scientific fields (e. g.
      epidemiology, gynecology and cardiology).

      The study started after all relevant legal and ethical requirements had been fulfilled.
      Information on the identity of the patients and treating physicians will be kept separated
      from the clinical information throughout the study. All relevant national data protection
      laws will be followed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine Perforation Rate</measure>
    <time_frame>12 months after insertion</time_frame>
    <description>Uterine perforation is a potentially serious complication of intrauterine device (IUD) use. The absolute risk of uterine perforation associated with the LNG IUS in routine medical practice has not hitherto been well defined. It is also unknown whether the perforation rate is higher with this IUD than with copper IUDs.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Contraceptive Failure</measure>
    <time_frame>Within 12 months</time_frame>
    <description>Intrauterine contraceptive methods have low Pearl Indices. Nevertheless, there is a lack of comparative data between LNG IUS users and copper IUD users. Women with unintended pregnancies were explicitly aked whether the pregnancy occured despite IUD use. The 29 pregnancies that occured after unrecognized IUD expulsion were considered to have resulted from a failure of the contraceptive method and were therefore included in the analysis.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">63194</enrollment>
  <condition>Uterine Perforation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Mirena®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Copper IUD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Recruitment of cohort members will be conducted via a network of approximately 2000
        gynecologists.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women who have a new insertion of an IUD

          -  women who are willing to participate in this cohort study

        Exclusion Criteria:

          -  women who are not cooperative

          -  women with a language barrier
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaas Heinemann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015 Apr;91(4):274-9. doi: 10.1016/j.contraception.2015.01.007. Epub 2015 Jan 16.</citation>
    <PMID>25601352</PMID>
  </results_reference>
  <results_reference>
    <citation>Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015 Apr;91(4):280-3. doi: 10.1016/j.contraception.2015.01.011. Epub 2015 Jan 16.</citation>
    <PMID>25601350</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2007</study_first_submitted>
  <study_first_submitted_qc>April 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2007</study_first_posted>
  <results_first_submitted>October 16, 2014</results_first_submitted>
  <results_first_submitted_qc>October 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2014</results_first_posted>
  <last_update_submitted>June 24, 2015</last_update_submitted>
  <last_update_submitted_qc>June 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Klaas Heinemann, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Uterine Perforation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Perforation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Overall, 63,194 patients were recruited for the EURAS-IUD study, and 1,746 patients were excluded due to protocol violations. Of these, information on the IUD inserted at baseline is missing for 859 women. Therefore, 859 recruited patients could not be assigned to one of the cohorts and are not counted in the table displaying the participant flow.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LNG IUS</title>
          <description>New users of Mirena® IUS</description>
        </group>
        <group group_id="P2">
          <title>Copper IUD</title>
          <description>New users of Copper IUD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43600">859 patients could not be assigned to a cohort and are therefore missing in the participant flow.</participants>
                <participants group_id="P2" count="18735">859 patients could not be assigned to a cohort and are therefore missing in the participant flow.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43078"/>
                <participants group_id="P2" count="18370"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="365"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="522"/>
                <participants group_id="P2" count="365"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LNG IUS</title>
          <description>New users of Mirena® IUS</description>
        </group>
        <group group_id="B2">
          <title>Copper IUD</title>
          <description>New users of Copper IUD</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43078"/>
            <count group_id="B2" value="18370"/>
            <count group_id="B3" value="61448"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43069"/>
                    <measurement group_id="B2" value="18370"/>
                    <measurement group_id="B3" value="61439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.37" spread="7.54"/>
                    <measurement group_id="B2" value="33.33" spread="7.64"/>
                    <measurement group_id="B3" value="36.2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43078"/>
                    <measurement group_id="B2" value="18370"/>
                    <measurement group_id="B3" value="61448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16981"/>
                    <measurement group_id="B2" value="6023"/>
                    <measurement group_id="B3" value="23004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6303"/>
                    <measurement group_id="B2" value="1947"/>
                    <measurement group_id="B3" value="8250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2280"/>
                    <measurement group_id="B2" value="585"/>
                    <measurement group_id="B3" value="2865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14190"/>
                    <measurement group_id="B2" value="6784"/>
                    <measurement group_id="B3" value="20974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2693"/>
                    <measurement group_id="B2" value="2018"/>
                    <measurement group_id="B3" value="4711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="631"/>
                    <measurement group_id="B2" value="1013"/>
                    <measurement group_id="B3" value="1644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Uterine Perforation Rate</title>
        <description>Uterine perforation is a potentially serious complication of intrauterine device (IUD) use. The absolute risk of uterine perforation associated with the LNG IUS in routine medical practice has not hitherto been well defined. It is also unknown whether the perforation rate is higher with this IUD than with copper IUDs.</description>
        <time_frame>12 months after insertion</time_frame>
        <population>Intention-to-treat (ITT) population. &quot;Number of Participants&quot; referring to the initially inserted IUS/IUD or the initial IUD insertion attempt.</population>
        <group_list>
          <group group_id="O1">
            <title>LNG IUS</title>
            <description>New users of Mirena® IUS</description>
          </group>
          <group group_id="O2">
            <title>Copper IUD</title>
            <description>New users of Copper IUD</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Perforation Rate</title>
          <description>Uterine perforation is a potentially serious complication of intrauterine device (IUD) use. The absolute risk of uterine perforation associated with the LNG IUS in routine medical practice has not hitherto been well defined. It is also unknown whether the perforation rate is higher with this IUD than with copper IUDs.</description>
          <population>Intention-to-treat (ITT) population. &quot;Number of Participants&quot; referring to the initially inserted IUS/IUD or the initial IUD insertion attempt.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43078"/>
                <count group_id="O2" value="18370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis to be tested was: The perforation incidence ratio for LNG IUS vs. copper IUD is higher than or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on a two group test of equivalence in proportions. These calculations are based on the following assumptions: 1) one sided α of 0.025; 2) power (1-β) of 0.80; 3) non-inferiority limit on hazard ratio of 2; and 4) an incidence of 0.5 and 1.0 per 1000 insertions.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>2.70</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for the following prognostic factors: age, BMI, breastfeeding at time of insertion and parity status.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis to be tested was: The perforation incidence ratio for LNG IUS vs. copper IUD is higher than or equal to 2.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculations were based on a two group test of equivalence in proportions. These calculations are based on the following assumptions: 1) one sided α of 0.025; 2) power (1-β) of 0.80; 3) non-inferiority limit on hazard ratio of 2; and 4) an incidence of 0.5 and 1.0 per 1000 insertions.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>2.78</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for the following prognostic factors: age, BMI, time since last delivery, experience of the inserting health care provider.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Contraceptive Failure</title>
        <description>Intrauterine contraceptive methods have low Pearl Indices. Nevertheless, there is a lack of comparative data between LNG IUS users and copper IUD users. Women with unintended pregnancies were explicitly aked whether the pregnancy occured despite IUD use. The 29 pregnancies that occured after unrecognized IUD expulsion were considered to have resulted from a failure of the contraceptive method and were therefore included in the analysis.</description>
        <time_frame>Within 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LNG IUS</title>
            <description>New users of Mirena® IUS</description>
          </group>
          <group group_id="O2">
            <title>Copper IUD</title>
            <description>New users of Copper IUD</description>
          </group>
        </group_list>
        <measure>
          <title>Contraceptive Failure</title>
          <description>Intrauterine contraceptive methods have low Pearl Indices. Nevertheless, there is a lack of comparative data between LNG IUS users and copper IUD users. Women with unintended pregnancies were explicitly aked whether the pregnancy occured despite IUD use. The 29 pregnancies that occured after unrecognized IUD expulsion were considered to have resulted from a failure of the contraceptive method and were therefore included in the analysis.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43078"/>
                <count group_id="O2" value="18370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pearl Index</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Pearl Index</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
            <estimate_desc>Hazard ratio was adjusted for the following prognostic factors: age, BMI, and parity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information on adverse events was collected over a time period of 12 months.</time_frame>
      <desc>All participants and health care providers were asked for adverse events at the follow-up 12 months after baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>LNG IUS</title>
          <description>New users of Mirena® IUS</description>
        </group>
        <group group_id="E2">
          <title>Copper IUD</title>
          <description>New users of Copper IUD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ICD10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="43078"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="18370"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43078"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18370"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43078"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18370"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43078"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18370"/>
              </event>
              <event>
                <sub_title>Other arterial thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43078"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43078"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18370"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In observational studies like EURAS-IUD, the possibility of bias and residual confounding can never be entirely eliminated. Thus, for risk estimates smaller than 2-fold, causality cannot be inferred confidently in view of alternative explanations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Klaas Heinemann</name_or_title>
      <organization>Center for Epidemiology and Health Research, Germany</organization>
      <phone>0049 (0) 30 945 101 20</phone>
      <email>k.heinemann@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

